Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

BACKGROUND: There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Claire F, Snyder Charen, Alexandra, Zhou, Qin, Carducci, Michael A, Buckley De Meritens, Alexandre, Corr, Bradley R, Fu, Siqing, Hollmann, Travis J, Iasonos, Alexia, Konner, Jason A, Konstantinopoulos, Panagiotis A, Modesitt, Susan C, Sharon, Elad, Aghajanian, Carol, Zamarin, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534695/
https://www.ncbi.nlm.nih.gov/pubmed/33004542
http://dx.doi.org/10.1136/jitc-2020-001126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534695/
https://www.ncbi.nlm.nih.gov/pubmed/33004542
http://dx.doi.org/10.1136/jitc-2020-001126

Ejemplares similares